A61K 47/50
The non-active ingredient being chemically bound to the active ingredient
Official title: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K47/50 (The non-active ingredient being chemically bound to the active ingredient) appears on 25,001 US grants and 41,399 published applications in this corpus.
Search patents in A61K- Granted patents
- 25,001
- Published applications
- 41,399
- Assignees
- 10,007
- Inventors
- 59,541
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 10 | 0 |
| 1977 | 12 | 0 |
| 1978 | 10 | 0 |
| 1979 | 6 | 0 |
| 1980 | 20 | 0 |
| 1981 | 12 | 0 |
| 1982 | 32 | 0 |
| 1983 | 23 | 0 |
| 1984 | 30 | 0 |
| 1985 | 29 | 0 |
| 1986 | 42 | 0 |
| 1987 | 46 | 0 |
| 1988 | 64 | 0 |
| 1989 | 84 | 0 |
| 1990 | 93 | 0 |
| 1991 | 120 | 0 |
| 1992 | 173 | 0 |
| 1993 | 183 | 0 |
| 1994 | 167 | 0 |
| 1995 | 202 | 0 |
| 1996 | 260 | 0 |
| 1997 | 383 | 0 |
| 1998 | 482 | 0 |
| 1999 | 395 | 0 |
| 2000 | 356 | 0 |
| 2001 | 350 | 122 |
| 2002 | 399 | 578 |
| 2003 | 352 | 917 |
| 2004 | 298 | 901 |
| 2005 | 264 | 924 |
| 2006 | 436 | 919 |
| 2007 | 338 | 858 |
| 2008 | 342 | 916 |
| 2009 | 420 | 1077 |
| 2010 | 516 | 1259 |
| 2011 | 550 | 1255 |
| 2012 | 627 | 1184 |
| 2013 | 813 | 1349 |
| 2014 | 973 | 1672 |
| 2015 | 1051 | 1829 |
| 2016 | 1169 | 2035 |
| 2017 | 1248 | 1976 |
| 2018 | 1284 | 2044 |
| 2019 | 1375 | 2293 |
| 2020 | 1409 | 2360 |
| 2021 | 1402 | 2551 |
| 2022 | 1272 | 2538 |
| 2023 | 1286 | 2621 |
| 2024 | 1307 | 2784 |
| 2025 | 1350 | 2514 |
| 2026 | 936 | 1923 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Composition containing buffer6 Oct 2026US 12,752,008 B2Perseus Proteomics Inc.
- Pharmaceutical composition containing anionic drug, and preparation method therefor6 Oct 2026US 12,752,010 B2Samyang Holdings Corporation
- Benzoheterocycle substituted tetrahydroisoquinoline compound6 Oct 2026US 12,752,011 B2Jiangxi Jemincare Group Co., Ltd
- EGFR degraders and associated methods of use6 Oct 2026US 12,752,012 B2BeOne Medicines | GmbH
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Microbiome-based GABA Cream with Chondroitin Sulfate Transdermal Delivery System8 Oct 2026US 2026/0306531 A1
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- Uncharged morpholino-based polymers having achiral intersubunit linkages1,700US 5,034,506 AAnti-Gene Development Group · 1991
- Polyhydroxyalkanoate compositions having controlled degradation rates1,516US 6,867,248 B1Metabolix, Inc. · 2005
- Medical scanning and treatment system and method1,502US 5,464,013 A1995
- Particle immobilized coatings and uses thereof1,386US 8,679,454 B2SurModics, Inc. · 2014